A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)
Clinical trial NCT06312176 · RECRUITING
Trial details
- NCT number
- NCT06312176
- Sponsor
- Merck Sharp & Dohme LLC
- Status
- RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2024-04-14
- Primary completion
- 2027-07-11
- Enrollment
- 1200
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.